An engineered exosome has been developed to deliver an antisense oligonucleotide (ASO) targeting STAT6 (exoASO-STAT6), which selectively silences the expression of STAT6 in tumor-associated macrophages (TAMs). This evidence concerns the gene STAT6 and neoplasm.